> [Go to French version](/fr/Règlements/Décrets,%20ordonnances%20et%20règlements%20statutaires/2019/124.md)

# Fees in Respect of Drugs and Medical Devices Order

**SOR/2019-124**

Enabling authorities: 
- [FOOD AND DRUGS ACT](/en/Acts/Revised%20Statutes%20of%20Canada/F/F-27.md)

Date registered: 8 May 2019

----------

Whereas, pursuant to section 30.62<sup><a href='#fn_a'>[a]</a></sup> of the [Food and Drugs Act](/en/Acts/Revised%20Statutes%20of%20Canada/F/F-27.md)<sup><a href='#fn_b'>[b]</a></sup>, the Minister of Health has consulted with any persons that the Minister considers to be interested in the matter;

Therefore, the Minister of Health, pursuant to subsections 30.61(1)<sup><a href='#fn_a'>[a]</a></sup> and 30.63(1)<sup><a href='#fn_a'>[a]</a></sup> of the [Food and Drugs Act](/en/Acts/Revised%20Statutes%20of%20Canada/F/F-27.md)<sup><a href='#fn_b'>[b]</a></sup>, makes the annexed Fees in Respect of Drugs and Medical Devices Order.

Ottawa, May 3, 2019
<p>Ginette C. Petitpas Taylor<br />Minister of Health<br /></p>



<a name='fn_a'><sup>a</sup></a>: S.C. 2017, c. 20, s. 317<br />

<a name='fn_b'><sup>b</sup></a>: R.S., c. F-27<br />


**PART 1** 
## General



### Interpretation



**Definitions**

**1** 

- **(1)** The following definitions apply in this Order.

***entity*** has the meaning assigned by the definition organization in section 2 of the [Criminal Code](/en/Acts/Revised%20Statutes%20of%20Canada/C/C-46.md). (*entité*)

***fiscal year*** means
- **(a)** for the purposes of sections 16, 17, 25, 26, 49, 53, 57, 66, 67, 74 and 79, the fiscal year of a person that provides information under that section or of a person with which the person is affiliated; and
- **(b)** for the purposes of any other section, the period beginning on April 1 in one year and ending on March 31 in the next year. (*exercice*)

***performance standard*** means the document entitled Performance Standards for the Fees in Respect of Drugs and Medical Devices Order, published by the Government of Canada, dated November 22, 2018. (*norme de rendement*)

***small business*** means a person in respect of which either of the following criteria applies:
- **(a)** the total of the number of employees of the person and of the persons with which the person is affiliated is fewer than 100; or
- **(b)** the total of the gross revenue of the person and of the persons with which the person is affiliated is $30,000 or more but less than $5 million. (*petite entreprise*)

**Other words and expressions**

- **(2)** Unless the context otherwise requires, other words and expressions used in this Order have the meanings assigned to them by the [Food and Drug Regulations](/en/Regulations/Consolidated%20Regulations%20of%20Canada/801-900/C.R.C.,%20c.%20870.md) or the [Medical Devices Regulations](/en/Regulations/Statutory%20Orders%20and%20Regulations/98/282.md), as the case may be.

**Affiliation**

- **(3)** For the purposes of this Order,
	- **(a)** one entity is affiliated with another entity if one of them is the subsidiary of the other or both are subsidiaries of the same entity or each of them is controlled by the same entity or individual;
	- **(b)** if two entities are affiliated with the same entity at the same time, they are deemed to be affiliated with each other; and
	- **(c)** an individual is affiliated with an entity if the individual controls the entity.

**Subsidiary entity**

- **(4)** For the purposes of this Order, an entity is a subsidiary of another entity if it is controlled by that other entity.

**Control**

- **(5)** For the purposes of this Order,
	- **(a)** a corporation is controlled by an entity or an individual if
		- **(i)** securities of the corporation to which are attached more than 50% of the votes that may be cast to elect directors of the corporation are held, directly or indirectly, whether through one or more subsidiaries or otherwise, other than by way of security only, by or for the benefit of that entity or individual, and
		- **(ii)** the votes attached to those securities are sufficient, if exercised, to elect a majority of the directors of the corporation; and
	- **(b)** an entity other than a corporation is controlled by an entity or individual if the entity or individual, directly or indirectly, whether through one or more subsidiaries or otherwise, holds an interest in the entity that is not a corporation that entitles them to receive more than 50% of the profits of that entity or more than 50% of its assets on dissolution.

**Deemed affiliation**

- **(6)** For the purposes of this Order, if it may reasonably be considered that one of the main reasons for the separate existence of two or more corporations is so that one of them meets the applicable conditions for a remission of a fee fixed under this Order for which only small businesses are eligible, the two or more corporations are deemed to be affiliated with each other.




### Purpose



**Purpose — fees**

**2** 

- **(1)** The purpose of this Order is to fix the fees for the following:
	- **(a)** in respect of drugs for human use and drugs for veterinary use only, the examination of a new drug submission, a supplement to a new drug submission, an abbreviated new drug submission or a supplement to an abbreviated new drug submission referred to in section C.08.002, C.08.002.1 or C.08.003 of the [Food and Drug Regulations](/en/Regulations/Consolidated%20Regulations%20of%20Canada/801-900/C.R.C.,%20c.%20870.md), as the case may be, an application in respect of an establishment licence filed under those Regulations or an application for a drug identification number filed under section C.01.014.1 of those Regulations;
	- **(b)** in respect of drugs for veterinary use only, the examination of a notification for a veterinary health product filed under subsection C.01.615(1) of the [Food and Drug Regulations](/en/Regulations/Consolidated%20Regulations%20of%20Canada/801-900/C.R.C.,%20c.%20870.md), a preclinical submission filed under subsection C.08.005(1) of those Regulations, information filed under section C.08.010 of those Regulations for the purpose of obtaining a letter of authorization, information and material filed under section C.08.014 of those Regulations for the purpose of obtaining an experimental studies certificate, information and material filed with the Minister in respect of a notifiable change or a protocol filed with the Minister;
	- **(c)** the right to sell a drug under the [Food and Drug Regulations](/en/Regulations/Consolidated%20Regulations%20of%20Canada/801-900/C.R.C.,%20c.%20870.md); and
	- **(d)** the examination of an application in respect of a medical device licence, the right to sell a medical device or the examination of an application in respect of an establishment licence under the [Medical Devices Regulations](/en/Regulations/Statutory%20Orders%20and%20Regulations/98/282.md).

**Purpose — remission**

- **(2)** The purpose of this Order is also to remit, in whole or in part, certain of those fees.




### Non-application



**Non-application**

**3** 

- **(1)** This Order does not apply in respect of
	- **(a)** publicly funded health care institutions;
	- **(b)** branches or agencies of the Government of Canada or of the government of a province; or
	- **(c)** drugs that are the subject of an extraordinary use new drug submission filed under section C.08.002.01 of the [Food and Drug Regulations](/en/Regulations/Consolidated%20Regulations%20of%20Canada/801-900/C.R.C.,%20c.%20870.md) or of an abbreviated extraordinary use new drug submission filed under section C.08.002.1 of those Regulations.

**Definition of publicly funded health care institution**

- **(2)** For the purposes of subsection (1), ***publicly funded health care institution*** means an institution that is funded by the Government of Canada or the government of a province and that is
	- **(a)** licensed, approved or designated by a province in accordance with the laws of the province to provide care or treatment to persons or animals suffering from any form of disease or illness; or
	- **(b)** owned or operated by the Government of Canada or the government of a province and that provides health services.




### Annual Adjustment of Fees



**Adjustment of fees**

**4** 

- **(1)** Beginning on April 1, 2021, every fee set out in this Order is to be adjusted in each fiscal year on April 1 by the percentage change over 12 months in the April All-items Consumer Price Index for Canada, as published by Statistics Canada under the [Statistics Act](/en/Acts/Revised%20Statutes%20of%20Canada/S/S-19.md), for the previous fiscal year and rounded up to the nearest dollar.

**Formula**

- **(2)** In the case of a fee that is payable under any of Divisions 1 to 5 of Part 2 or Division 1 of Part 3 in a fiscal year that is not set out in the applicable schedule, the amount of the fee is to be calculated, on April 1 of the fiscal year, in accordance with the following formula and rounded up to the nearest dollar:
```
Fee = A + (A × B)
```
where
- **A** is the amount of the fee that was payable in the previous fiscal year; and
- **B** is the percentage change over 12 months in the April All-items Consumer Price Index for Canada, as published by Statistics Canada under the [Statistics Act](/en/Acts/Revised%20Statutes%20of%20Canada/S/S-19.md), for the previous fiscal year.




### Requests for Information — Remissions for Small Businesses



**Information on request**

**5** If the Minister determines, in respect of a person that provided information under any of the following provisions, that additional information is necessary to demonstrate that the person met the definition small business in subsection 1(1) in the applicable fiscal year, the Minister may request that the person provide him or her with additional information within 60 days after the day on which the request is made:
- **(a)** subparagraph 16(a)(ii) or (b)(ii);
- **(b)** clause 17(b)(i)(B) or (ii)(B);
- **(c)** subparagraph 25(a)(ii) or (b)(ii);
- **(d)** clause 26(b)(i)(B) or (ii)(B);
- **(e)** subparagraph 49(a)(ii) or (b)(ii);
- **(f)** subparagraph 53(a)(ii) or (b)(ii);
- **(g)** subparagraph 57(a)(ii) or (b)(ii);
- **(h)** subparagraph 66(a)(ii) or (b)(ii);
- **(i)** clause 67(b)(i)(B) or (ii)(B);
- **(j)** subparagraph 74(a)(ii) or (b)(ii); or
- **(k)** subparagraph 79(a)(ii) or (b)(ii).




### Performance Standard and Remission



**Remission — performance standard**

**6** 

- **(1)** If the Minister determines that the performance standard has not been met in relation to a fee that is payable under this Order, remission is granted to the person that must pay the fee
	- **(a)** of an amount equal to 25% of the fee; or
	- **(b)** of an amount equal to 25% of the amount that is payable, in the case where remission is granted of part of the fee under any other provision of this Order.

**Exceptions**

- **(2)** Subsection (1) does not apply to a fee for the examination of
	- **(a)** an application or submission referred to in this Order in respect of which a joint or parallel review is conducted by the Minister and a foreign regulatory authority; or
	- **(b)** an application for a licence that is filed under section 32 of the [Medical Devices Regulations](/en/Regulations/Statutory%20Orders%20and%20Regulations/98/282.md) if
		- **(i)** the medical device to which the application relates includes a component that is a drug, and
		- **(ii)** the Minister has made a decision in respect of the application to issue or amend a medical device licence under section 36 of those Regulations, or to refuse to issue or amend such a licence under section 38 of those Regulations.




**PART 2** 
## Drugs



**DIVISION 1** 
### Fees for Examination of a Submission — Drugs for Human Use



#### Interpretation



**Definition of submission**

**7** In this Division, ***submission*** means any of the following:
- **(a)** an application for a drug identification number that is filed under section C.01.014.1 of the [Food and Drug Regulations](/en/Regulations/Consolidated%20Regulations%20of%20Canada/801-900/C.R.C.,%20c.%20870.md);
- **(b)** a new drug submission that is filed under section C.08.002 of those Regulations;
- **(c)** an abbreviated new drug submission that is filed under section C.08.002.1 of those Regulations; or
- **(d)** a supplement to a new drug submission or abbreviated new drug submission that is filed under section C.08.003 of those Regulations.




#### Non-application



**Non-application**

**8** This Division does not apply to drugs for veterinary use only.




#### Fees and Remissions



**Fee for examination**

**9** 

- **(1)** Subject to paragraph 10(b) and section 12, the fee for the examination of a submission is, in respect of the applicable submission class set out in column 1 of Schedule 1 and described in column 2, as follows:
	- **(a)** in the case of a fee that is payable in a fiscal year set out in any of columns 3 to 6 of Schedule 1, the fee set out in that column; and
	- **(b)** in the case of a fee that is payable in a fiscal year other than one set out in any of columns 3 to 6 of Schedule 1, the amount that is calculated in accordance with subsection 4(2).

**Fee paid by person that files submission**

- **(2)** The fee is payable by the person that files the submission.




**Fee and timing of payment — preliminary examination**

**10** If a preliminary examination is conducted in respect of a submission,
- **(a)** the full fee is payable on the issuance by the Minister of a notice to the person referred to in subsection 9(2) stating that the submission has been found to be complete and has been accepted for further examination; or
- **(b)** 10% of the fee is payable on the issuance by the Minister of a notice to the person referred to in subsection 9(2) stating that the submission has been found to be incomplete.




**Fee and timing of payment — no preliminary examination**

**11** If a preliminary examination is not conducted in respect of a submission, the fee is payable on the issuance by the Minister of a notice to the person referred to in subsection 9(2) stating that the submission has been received.




**Fee — filing in previous fiscal year**

**12** For the purposes of subsection 9(1), if the Minister issues a notice referred to in section 10 or 11 in the fiscal year that follows the fiscal year in which the submission was filed, the fee that is payable is the fee that was payable in the fiscal year in which the submission was filed.




**Deferred payment — notice of compliance**

**13** Despite sections 10 and 11, if the person referred to in subsection 9(2) files an application for authorization under section C.07.003 of the [Food and Drug Regulations](/en/Regulations/Consolidated%20Regulations%20of%20Canada/801-900/C.R.C.,%20c.%20870.md) at the same time that the person files the submission, payment of the fee is deferred until the issuance to the person of a notice of compliance under section C.08.004 of those Regulations or of a document setting out the drug identification number assigned for the drug under subsection C.01.014.2(1) of those Regulations.




**Remission — urgent public health need**

**14** Remission is granted to a person referred to in subsection 9(2) that files a new drug submission under section C.08.002 of the [Food and Drug Regulations](/en/Regulations/Consolidated%20Regulations%20of%20Canada/801-900/C.R.C.,%20c.%20870.md) or an application for a drug identification number under section C.01.014.1 of those Regulations of the amount of the fee that is payable under subsection 9(1) if, as of the day on which the person filed the new drug submission or application,
- **(a)** the drug has the same medicinal ingredient, strength and route of administration and is in a comparable dosage form as a drug that may be imported under subsection C.10.001(2) of those Regulations;
- **(b)** a drug identification number has not been assigned under subsection C.01.014.2(1) of those Regulations for the drug or for another drug that has the same medicinal ingredient, strength and route of administration and is in a comparable dosage form; and
- **(c)** a notice of compliance has not been issued under section C.08.004 of those Regulations in respect of the drug or another drug that has the same medicinal ingredient, strength and route of administration and is in a comparable dosage form.




**Remission — General Council Decision**

**15** Remission is granted to the person referred to in subsection 9(2) of the amount of the fee that is payable under subsection 9(1) if the person has received an authorization under section 21.04 of the [Patent Act](/en/Acts/Revised%20Statutes%20of%20Canada/P/P-4.md) in respect of the drug.




**Remission — small business**

**16** Subject to section 18, remission is granted to the person referred to in subsection 9(2) of an amount equal to 50% of the fee that is payable under subsection 9(1) if the person provides with their submission, in a form established by the Minister,
- **(a)** in the case where the person has completed their first fiscal year,
	- **(i)** a statement indicating that the person met the definition small business in subsection 1(1) in their last completed fiscal year, and
	- **(ii)** the following information:
		- **(A)** a list of the persons with which the person was affiliated in the person’s last completed fiscal year,
		- **(B)** the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person was affiliated in the person’s last completed fiscal year,
		- **(C)** the number of employees of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year, and
		- **(D)** the gross revenue of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year; and
- **(b)** in the case where the person has not completed their first fiscal year,
	- **(i)** a statement indicating that the person anticipates meeting the definition small business in subsection 1(1) in their first fiscal year, and
	- **(ii)** the following information:
		- **(A)** a list of the persons with which the person is affiliated in the person’s first fiscal year,
		- **(B)** the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person is affiliated in the person’s first fiscal year,
		- **(C)** the number of employees of the person in their first fiscal year and of the persons with which the person is affiliated in those persons’ last completed fiscal year, and
		- **(D)** the projected gross revenue of the person in their first fiscal year and the gross revenue of the persons with which the person is affiliated in those persons’ last completed fiscal year.




**Remission — first submission by small business**

**17** Subject to section 18, remission is granted to the person referred to in subsection 9(2) of an amount equal to the fee that is payable under subsection 9(1) if the following conditions are met:
- **(a)** the person has not previously filed a submission in respect of a drug; and
- **(b)** the person provides with their submission, in a form established by the Minister,
	- **(i)** in the case where the person has completed their first fiscal year,
		- **(A)** a statement indicating that the person met the definition small business in subsection 1(1) in their last completed fiscal year, and
		- **(B)** the following information:
			- **(I)** a list of the persons with which the person was affiliated in the person’s last completed fiscal year,
			- **(II)** the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person was affiliated in the person’s last completed fiscal year,
			- **(III)** the number of employees of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year, and
			- **(IV)** the gross revenue of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year, and
	- **(ii)** in the case where the person has not completed their first fiscal year,
		- **(A)** a statement indicating that the person anticipates meeting the definition small business in subsection 1(1) in their first fiscal year, and
		- **(B)** the following information:
			- **(I)** a list of the persons with which the person is affiliated in the person’s first fiscal year,
			- **(II)** the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person is affiliated in the person’s first fiscal year,
			- **(III)** the number of employees of the person in their first fiscal year and of the persons with which the person is affiliated in those persons’ last completed fiscal year, and
			- **(IV)** the projected gross revenue of the person in their first fiscal year and the gross revenue of the persons with which the person is affiliated in those persons’ last completed fiscal year.




**Fee or difference payable**

**18** If the Minister requests under section 5 that the person referred to in subsection 9(2) provide additional information, the fee — or the difference between the fee payable under subsection 9(1) and the amount already paid, as the case may be — is immediately payable if
- **(a)** the person has not provided, within the period specified in section 5, the Minister with additional information for the purpose of demonstrating that the person met the definition small business in subsection 1(1) in the applicable fiscal year; or
- **(b)** the person has provided, within the period specified in section 5, the Minister with additional information for the purpose of demonstrating that the person met the definition in the applicable fiscal year but the Minister determines, after the period ends, that the person has not provided sufficient information to demonstrate that they met that definition in the applicable fiscal year.




**DIVISION 2** 
### Fees for Examination of a Submission — Drugs for Veterinary Use Only



#### Interpretation



**Definition of submission**

**19** In this Division, ***submission*** means any of the following:
- **(a)** an application for a drug identification number that is filed under section C.01.014.1 of the [Food and Drug Regulations](/en/Regulations/Consolidated%20Regulations%20of%20Canada/801-900/C.R.C.,%20c.%20870.md);
- **(b)** a notification that is filed under subsection C.01.615(1) of those Regulations in respect of a veterinary health product;
- **(c)** a new drug submission that is filed under section C.08.002 of those Regulations;
- **(d)** an abbreviated new drug submission that is filed under section C.08.002.1 of those Regulations;
- **(e)** a supplement to a new drug submission or an abbreviated new drug submission that is filed under section C.08.003 of those Regulations;
- **(f)** a preclinical submission that is filed under subsection C.08.005(1) of those Regulations;
- **(g)** information that is filed under section C.08.010 of those Regulations for the purpose of obtaining a letter of authorization;
- **(h)** information and material that is filed under section C.08.014 of those Regulations for the purpose of obtaining an experimental studies certificate;
- **(i)** information and material that is filed with the Minister in respect of a notifiable change; or
- **(j)** a protocol that is filed with the Minister and may support any of the matters referred to in paragraphs (c) to (f) or (h).




#### Application



**Application**

**20** This Division applies to drugs for veterinary use only.




#### Fees and Remissions



**Fee for examination**

**21** 

- **(1)** Subject to paragraph 22(b) and section 24, the fee that is payable in respect of a submission that is of a type set out in column 1 of Schedule 2, for the examination of each component set out in column 2 that is included in the submission, is as follows:
	- **(a)** in the case of a fee that is payable in a fiscal year set out in any of columns 3 to 9 of Schedule 2, the applicable fee set out in that column; and
	- **(b)** in the case of a fee that is payable in a fiscal year other than one set out in any of columns 3 to 9 of Schedule 2, the amount that is calculated in accordance with subsection 4(2).

**Fee paid by person that files submission**

- **(2)** The fee is payable by the person that files the submission.




**Fee and timing of payment — preliminary examination**

**22** If a preliminary examination is conducted in respect of a submission,
- **(a)** the full fee is payable on the issuance by the Minister of a notice to the person referred to in subsection 21(2) stating that the submission has been found to be complete and has been accepted for further examination; or
- **(b)** 10% of the fee is payable on the issuance by the Minister of a notice to the person referred to in subsection 21(2) stating that the submission has been found to be incomplete.




**Fee and timing of payment — no preliminary examination**

**23** If a preliminary examination is not conducted in respect of a submission, the fee is payable on the issuance by the Minister of a notice to the person referred to in subsection 21(2) stating that the submission has been received.




**Fee — filing in previous fiscal year**

**24** For the purposes of subsection 21(1), if the Minister issues a notice referred to in section 22 or 23 in the fiscal year that follows the fiscal year in which the submission was filed, the fee that is payable is the fee that was payable in the fiscal year in which the submission was filed.




**Remission — small business**

**25** Subject to section 27, remission is granted to the person referred to in subsection 21(2) of an amount equal to 50% of the fee that is payable under subsection 21(1) if the person provides with their submission, in a form established by the Minister,
- **(a)** in the case where the person has completed their first fiscal year,
	- **(i)** a statement indicating that the person met the definition small business in subsection 1(1) in their last completed fiscal year, and
	- **(ii)** the following information:
		- **(A)** a list of the persons with which the person was affiliated in the person’s last completed fiscal year,
		- **(B)** the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person was affiliated in the person’s last completed fiscal year,
		- **(C)** the number of employees of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year, and
		- **(D)** the gross revenue of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year; and
- **(b)** in the case where the person has not completed their first fiscal year,
	- **(i)** a statement indicating that the person anticipates meeting the definition small business in subsection 1(1) in their first fiscal year, and
	- **(ii)** the following information:
		- **(A)** a list of the persons with which the person is affiliated in the person’s first fiscal year,
		- **(B)** the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person is affiliated in the person’s first fiscal year,
		- **(C)** the number of employees of the person in their first fiscal year and of the persons with which the person is affiliated in those persons’ last completed fiscal year, and
		- **(D)** the projected gross revenue of the person in their first fiscal year and the gross revenue of the persons with which the person is affiliated in those persons’ last completed fiscal year.




**Remission — first submission by small business**

**26** Subject to section 27, remission is granted to the person referred to in subsection 21(2) of an amount equal to the fee that is payable under subsection 21(1) if the following conditions are met:
- **(a)** the person has not previously filed a submission in respect of a drug; and
- **(b)** the person provides with their submission, in a form established by the Minister,
	- **(i)** in the case where the person has completed their first fiscal year,
		- **(A)** a statement indicating that the person met the definition small business in subsection 1(1) in their last completed fiscal year, and
		- **(B)** the following information:
			- **(I)** a list of the persons with which the person was affiliated in the person’s last completed fiscal year,
			- **(II)** the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person was affiliated in the person’s last completed fiscal year,
			- **(III)** the number of employees of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year, and
			- **(IV)** the gross revenue of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year, and
	- **(ii)** in the case where the person has not completed their first fiscal year,
		- **(A)** a statement indicating that the person anticipates meeting the definition small business in subsection 1(1) in their first fiscal year, and
		- **(B)** the following information:
			- **(I)** a list of the persons with which the person is affiliated in the person’s first fiscal year,
			- **(II)** the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person is affiliated in the person’s first fiscal year,
			- **(III)** the number of employees of the person in their first fiscal year and of the persons with which the person is affiliated in those persons’ last completed fiscal year, and
			- **(IV)** the projected gross revenue of the person in their first fiscal year and the gross revenue of the persons with which the person is affiliated in those persons’ last completed fiscal year.




**Fee or difference payable**

**27** If the Minister requests under section 5 that the person referred to in subsection 21(2) provide additional information, the fee — or the difference between the fee payable under subsection 21(1) and the amount already paid, as the case may be — is immediately payable if
- **(a)** the person has not provided, within the period specified in section 5, the Minister with additional information for the purpose of demonstrating that the person met the definition small business in subsection 1(1) in the applicable fiscal year; or
- **(b)** the person has provided, within the period specified in section 5, the Minister with additional information for the purpose of demonstrating that the person met the definition in the applicable fiscal year but the Minister determines, after the period ends, that the person has not provided sufficient information to demonstrate that they met that definition in the applicable fiscal year.




**DIVISION 3** 
### Fees for Examination of an Application for an Establishment Licence — Drugs



#### Interpretation



**Definitions**

**28** The following definitions apply in this Division.

***activity*** means an activity set out in Table I to section C.01A.008 of the [Food and Drug Regulations](/en/Regulations/Consolidated%20Regulations%20of%20Canada/801-900/C.R.C.,%20c.%20870.md). (*activité*)

***drug*** has the same meaning as in subsection C.01A.001(2) of the [Food and Drug Regulations](/en/Regulations/Consolidated%20Regulations%20of%20Canada/801-900/C.R.C.,%20c.%20870.md). (*drogue*)

***establishment licence*** means a licence issued under section C.01A.008 of the [Food and Drug Regulations](/en/Regulations/Consolidated%20Regulations%20of%20Canada/801-900/C.R.C.,%20c.%20870.md). (*licence d’établissement*)




#### Fees and Remission



**Fee for examination**

**29** 

- **(1)** Subject to section 48, the fee for the examination of an application for an establishment licence or for the annual review of an establishment licence is the sum of the applicable fees referred to in sections 33 to 40 and the fee payable for the examination of an application to amend an establishment licence to add a building is the sum of the applicable fees referred to in sections 41 to 47.

**Fee paid by person that files application**

- **(2)** The fee is payable by the person that files the application.




**Timing of payment**

**30** The fee is payable on the issuance by the Minister of a notice to the person referred to in subsection 29(2) stating that the application has been accepted for further examination.




**Reinstatement**

**31** Every provision of this Division that applies to an application for an establishment licence also applies to a request to have such a licence reinstated following the correction of the situation that gave rise to its suspension.




**Interpretation**

**32** In sections 33 to 39, a reference to the examination of an application for an establishment licence includes an examination of an application for the annual review of an establishment licence.




**Fee — licence authorizing sterile fabrication**

**33** For the examination of an application for an establishment licence for each building at which one or more activities are to be conducted, including fabricating drugs in sterile dosage form, the fee is as follows:
- **(a)** in respect of drugs for human use,
	- **(i)** in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 5 of Schedule 3, the fee set out in item 1 for that fiscal year, and
	- **(ii)** in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 5 of Schedule 3, the amount that is calculated in accordance with subsection 4(2); and
- **(b)** in respect of drugs for veterinary use only,
	- **(i)** in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 8 of Schedule 4, the fee set out in item 1 for that fiscal year, and
	- **(ii)** in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 8 of Schedule 4, the amount that is calculated in accordance with subsection 4(2).




**Fee — licence authorizing importation**

**34** For the examination of an application for an establishment licence for each building at which one or more activities are to be conducted, including importing drugs — but not fabricating drugs in sterile dosage form — the fee is as follows:
- **(a)** in respect of drugs for human use,
	- **(i)** in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 5 of Schedule 3, the fee set out in item 2 for that fiscal year, and
	- **(ii)** in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 5 of Schedule 3, the amount that is calculated in accordance with subsection 4(2); and
- **(b)** in respect of drugs for veterinary use only,
	- **(i)** in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 8 of Schedule 4, the fee set out in item 2 for that fiscal year, and
	- **(ii)** in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 8 of Schedule 4, the amount that is calculated in accordance with subsection 4(2).




**Fee — licence authorizing non-sterile fabrication**

**35** For the examination of an application for an establishment licence for each building at which one or more activities are to be conducted, including fabricating drugs that are not in sterile dosage form — but not fabricating drugs in sterile dosage form or importing drugs — the fee is as follows:
- **(a)** in respect of drugs for human use,
	- **(i)** in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 5 of Schedule 3, the fee set out in item 3 for that fiscal year, and
	- **(ii)** in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 5 of Schedule 3, the amount that is calculated in accordance with subsection 4(2); and
- **(b)** in respect of drugs for veterinary use only,
	- **(i)** in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 8 of Schedule 4, the fee set out in item 3 for that fiscal year, and
	- **(ii)** in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 8 of Schedule 4, the amount that is calculated in accordance with subsection 4(2).




**Fee — licence authorizing distribution**

**36** For the examination of an application for an establishment licence for each building at which one or more activities are to be conducted, including distributing drugs — but not fabricating drugs in sterile dosage form, importing drugs or fabricating drugs that are not in sterile dosage form — the fee is as follows:
- **(a)** in respect of drugs for human use,
	- **(i)** in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 5 of Schedule 3, the fee set out in item 4 for that fiscal year, and
	- **(ii)** in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 5 of Schedule 3, the amount that is calculated in accordance with subsection 4(2); and
- **(b)** in respect of drugs for veterinary use only,
	- **(i)** in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 8 of Schedule 4, the fee set out in item 4 for that fiscal year, and
	- **(ii)** in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 8 of Schedule 4, the amount that is calculated in accordance with subsection 4(2).




**Fee — licence authorizing wholesaling**

**37** For the examination of an application for an establishment licence for each building at which one or more activities are to be conducted, including wholesaling drugs — but not fabricating drugs in sterile dosage form, importing drugs, fabricating drugs that are not in sterile dosage form or distributing drugs — the fee is as follows:
- **(a)** in respect of drugs for human use,
	- **(i)** in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 5 of Schedule 3, the fee set out in item 5 for that fiscal year, and
	- **(ii)** in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 5 of Schedule 3, the amount that is calculated in accordance with subsection 4(2); and
- **(b)** in respect of drugs for veterinary use only,
	- **(i)** in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 8 of Schedule 4, the fee set out in item 5 for that fiscal year, and
	- **(ii)** in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 8 of Schedule 4, the amount that is calculated in accordance with subsection 4(2).




**Fee — licence authorizing packaging/labelling**

**38** For the examination of an application for an establishment licence for each building at which one or more activities are to be conducted, including packaging/labelling drugs — but not fabricating drugs in sterile dosage form, importing drugs, fabricating drugs that are not in sterile dosage form, distributing drugs or wholesaling drugs — the fee is as follows:
- **(a)** in respect of drugs for human use,
	- **(i)** in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 5 of Schedule 3, the fee set out in item 6 for that fiscal year, and
	- **(ii)** in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 5 of Schedule 3, the amount that is calculated in accordance with subsection 4(2); and
- **(b)** in respect of drugs for veterinary use only,
	- **(i)** in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 8 of Schedule 4, the fee set out in item 6 for that fiscal year, and
	- **(ii)** in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 8 of Schedule 4, the amount that is calculated in accordance with subsection 4(2).




**Fee — licence authorizing testing**

**39** For the examination of an application for an establishment licence for each building at which one or more activities are to be conducted, including testing drugs — but not fabricating drugs in sterile dosage form, importing drugs, fabricating drugs that are not in sterile dosage form, distributing drugs, wholesaling drugs or packaging/labelling drugs — the fee is as follows:
- **(a)** in respect of drugs for human use,
	- **(i)** in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 5 of Schedule 3, the fee set out in item 7 for that fiscal year, and
	- **(ii)** in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 5 of Schedule 3, the amount that is calculated in accordance with subsection 4(2); and
- **(b)** in respect of drugs for veterinary use only,
	- **(i)** in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 8 of Schedule 4, the fee set out in item 7 for that fiscal year, and
	- **(ii)** in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 8 of Schedule 4, the amount that is calculated in accordance with subsection 4(2).




**Fee — application for licence — building outside Canada**

**40** 

- **(1)** For the examination of an application for an establishment licence referred to in section 33 or 34, the fee for each building located outside Canada that is listed on the application is
	- **(a)** in respect of drugs for human use, $918; and
	- **(b)** in respect of drugs for veterinary use only,
		- **(i)** in the case of a fee that is payable in the fiscal year 2020-2021, $765; and
		- **(ii)** in the case of a fee that is payable in any subsequent fiscal year, $918.

**Fee — application for annual review — building outside Canada**

- **(2)** For the examination of an application for the annual review of an establishment licence referred to in section 33 or 34, the fee for each building located outside Canada that is listed on the establishment licence is the applicable fee set out in paragraph (1)(a) or (b).




**Fee — amendment — licence authorizing sterile fabrication**

**41** If an application to amend an establishment licence seeks to add a building and the amendment seeks to authorize the holder to fabricate drugs in sterile dosage form at that building, the fee for the examination of the application for each building to be added is as follows:
- **(a)** in respect of drugs for human use,
	- **(i)** in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 5 of Schedule 3, the fee set out in item 1 for that fiscal year, and
	- **(ii)** in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 5 of Schedule 3, the amount that is calculated in accordance with subsection 4(2); and
- **(b)** in respect of drugs for veterinary use only,
	- **(i)** in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 8 of Schedule 4, the fee set out in item 1 for that fiscal year, and
	- **(ii)** in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 8 of Schedule 4, the amount that is calculated in accordance with subsection 4(2).




**Fee — amendment — licence authorizing importation**

**42** If an application to amend an establishment licence seeks to add a building and the amendment seeks to authorize the holder to import drugs — but not to fabricate drugs in sterile dosage form — at that building, the fee for the examination of the application for each building to be added is as follows:
- **(a)** in respect of drugs for human use,
	- **(i)** in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 5 of Schedule 3, the fee set out in item 2 for that fiscal year, and
	- **(ii)** in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 5 of Schedule 3, the amount that is calculated in accordance with subsection 4(2); and
- **(b)** in respect of drugs for veterinary use only,
	- **(i)** in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 8 of Schedule 4, the fee set out in item 2 for that fiscal year, and
	- **(ii)** in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 8 of Schedule 4, the amount that is calculated in accordance with subsection 4(2).




**Fee — amendment — licence authorizing non-sterile fabrication**

**43** If an application to amend an establishment licence seeks to add a building and the amendment seeks to authorize the holder to fabricate drugs that are not in sterile dosage form — but not to fabricate drugs in sterile dosage form or import drugs — at that building, the fee for the examination of the application for each building to be added is as follows:
- **(a)** in respect of drugs for human use,
	- **(i)** in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 5 of Schedule 3, the fee set out in item 3 for that fiscal year, and
	- **(ii)** in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 5 of Schedule 3, the amount that is calculated in accordance with subsection 4(2); and
- **(b)** in respect of drugs for veterinary use only,
	- **(i)** in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 8 of Schedule 4, the fee set out in item 3 for that fiscal year, and
	- **(ii)** in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 8 of Schedule 4, the amount that is calculated in accordance with subsection 4(2).




**Fee — amendment — licence authorizing distribution**

**44** If an application to amend an establishment licence seeks to add a building and the amendment seeks to authorize the holder to distribute drugs — but not to fabricate drugs in sterile dosage form, import drugs or fabricate drugs that are not in sterile dosage form — at that building, the fee for the examination of the application for each building to be added is as follows:
- **(a)** in respect of drugs for human use,
	- **(i)** in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 5 of Schedule 3, the fee set out in item 4 for that fiscal year, and
	- **(ii)** in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 5 of Schedule 3, the amount that is calculated in accordance with subsection 4(2); and
- **(b)** in respect of drugs for veterinary use only,
	- **(i)** in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 8 of Schedule 4, the fee set out in item 4 for that fiscal year, and
	- **(ii)** in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 8 of Schedule 4, the amount that is calculated in accordance with subsection 4(2).




**Fee — amendment — licence authorizing wholesaling**

**45** If an application to amend an establishment licence seeks to add a building and the amendment seeks to authorize the holder to wholesale drugs — but not to fabricate drugs in sterile dosage form, import drugs, fabricate drugs that are not in sterile dosage form or distribute drugs — at that building, the fee for the examination of the application for each building to be added is as follows:
- **(a)** in respect of drugs for human use,
	- **(i)** in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 5 of Schedule 3, the fee set out in item 5 for that fiscal year, and
	- **(ii)** in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 5 of Schedule 3, the amount that is calculated in accordance with subsection 4(2); and
- **(b)** in respect of drugs for veterinary use only,
	- **(i)** in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 8 of Schedule 4, the fee set out in item 5 for that fiscal year, and
	- **(ii)** in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 8 of Schedule 4, the amount that is calculated in accordance with subsection 4(2).




**Fee — amendment — licence authorizing packaging/labelling**

**46** If an application to amend an establishment licence seeks to add a building and the amendment seeks to authorize the holder to package/label drugs — but not to fabricate drugs in sterile dosage form, import drugs, fabricate drugs that are not in sterile dosage form, distribute drugs or wholesale drugs — at that building, the fee for the examination of the application for each building to be added is as follows:
- **(a)** in respect of drugs for human use,
	- **(i)** in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 5 of Schedule 3, the fee set out in item 6 for that fiscal year, and
	- **(ii)** in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 5 Schedule 3, the amount that is calculated in accordance with subsection 4(2); and
- **(b)** in respect of drugs for veterinary use only,
	- **(i)** in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 8 of Schedule 4, the fee set out in item 6 for that fiscal year, and
	- **(ii)** in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 8 of Schedule 4, the amount that is calculated in accordance with subsection 4(2).




**Fee — amendment — licence authorizing testing**

**47** If an application to amend an establishment licence seeks to add a building and the amendment seeks to authorize the holder to test drugs — but not to fabricate drugs in sterile dosage form, import drugs, fabricate drugs that are not in sterile dosage form, distribute drugs, wholesale drugs or package/label drugs — at that building, the fee for the examination of the application for each building to be added is as follows:
- **(a)** in respect of drugs for human use,
	- **(i)** in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 5 of Schedule 3, the fee set out in item 7 for that fiscal year, and
	- **(ii)** in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 5 of Schedule 3, the amount that is calculated in accordance with subsection 4(2); and
- **(b)** in respect of drugs for veterinary use only,
	- **(i)** in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 8 of Schedule 4, the fee set out in item 7 for that fiscal year, and
	- **(ii)** in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 8 of Schedule 4, the amount that is calculated in accordance with subsection 4(2).




**Prorated fee**

**48** The fee that is payable under subsection 29(1) is reduced by the percentage set out in column 1 of Schedule 5 if the person referred to in subsection 29(2) files, in the period set out in column 2,
- **(a)** an application for an establishment licence and has not previously filed such an application; or
- **(b)** an application to amend an establishment licence that seeks to add a building.




**Remission — small business**

**49** Subject to section 50, remission is granted to the person referred to in subsection 29(2) of an amount equal to 25% of the fee that is payable under subsection 29(1) if the person provides with their application, in a form established by the Minister,
- **(a)** in the case where the person has completed their first fiscal year,
	- **(i)** a statement indicating that the person met the definition small business in subsection 1(1) in their last completed fiscal year, and
	- **(ii)** the following information:
		- **(A)** a list of the persons with which the person was affiliated in the person’s last completed fiscal year,
		- **(B)** the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person was affiliated in the person’s last completed fiscal year,
		- **(C)** the number of employees of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year, and
		- **(D)** the gross revenue of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year; and
- **(b)** in the case where the person has not completed their first fiscal year,
	- **(i)** a statement indicating that the person anticipates meeting the definition small business in subsection 1(1) in their first fiscal year, and
	- **(ii)** the following information:
		- **(A)** a list of the persons with which the person is affiliated in the person’s first fiscal year,
		- **(B)** the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person is affiliated in the person’s first fiscal year,
		- **(C)** the number of employees of the person in their first fiscal year and of the persons with which the person is affiliated in those persons’ last completed fiscal year, and
		- **(D)** the projected gross revenue of the person in their first fiscal year and the gross revenue of the persons with which the person is affiliated in those persons’ last completed fiscal year.




**Difference payable**

**50** If the Minister requests under section 5 that the person referred to in subsection 29(2) provide additional information, the difference between the fee payable under subsection 29(1) and the amount already paid is immediately payable if
- **(a)** the person has not provided, within the period specified in section 5, the Minister with additional information for the purpose of demonstrating that the person met the definition small business in subsection 1(1) in the applicable fiscal year; or
- **(b)** the person has provided, within the period specified in section 5, the Minister with additional information for the purpose of demonstrating that the person met the definition in the applicable fiscal year but the Minister determines, after the period ends, that the person has not provided sufficient information to demonstrate that they met that definition in the applicable fiscal year.




**DIVISION 4** 
### Fees for Right to Sell Drugs for Human Use



#### Non-application



**Non-application**

**51** This Division does not apply to drugs for veterinary use only.




#### Fees and Remission



**Annual fee**

**52** 

- **(1)** The annual fee that is payable for the right to sell a drug for which a drug identification number has been assigned under subsection C.01.014.2(1) of the [Food and Drug Regulations](/en/Regulations/Consolidated%20Regulations%20of%20Canada/801-900/C.R.C.,%20c.%20870.md) is, in respect of the type of drug set out in column 1 of Schedule 6, as follows:
	- **(a)** in the case of a fee that is payable in a fiscal year set out in any of columns 2 to 5 of Schedule 6, the fee set out in that column; and
	- **(b)** in the case of a fee that is payable in a fiscal year other than one set out in any of columns 2 to 5 of Schedule 6, the amount that is calculated in accordance with subsection 4(2).

**Fee payable by person after first sale**

- **(2)** The fee is payable by the person to which a document was issued under subsection C.01.014.2(1) of the [Food and Drug Regulations](/en/Regulations/Consolidated%20Regulations%20of%20Canada/801-900/C.R.C.,%20c.%20870.md) that sets out the drug identification number assigned for the drug if the person has sold the drug following the issuance of the document.

**Timing of payment**

- **(3)** The fee is payable on October 1.

**Non-application — interruption of sale**

- **(4)** Subject to subsection (5), subsection (1) does not apply to the person if they notified the Minister in accordance with section C.01.014.71 of the [Food and Drug Regulations](/en/Regulations/Consolidated%20Regulations%20of%20Canada/801-900/C.R.C.,%20c.%20870.md) in the 12 months preceding October 1.

**Resumption of sale**

- **(5)** Subsection (4) ceases to apply on the day on which the person notifies the Minister in accordance with section C.01.014.72 of the [Food and Drug Regulations](/en/Regulations/Consolidated%20Regulations%20of%20Canada/801-900/C.R.C.,%20c.%20870.md).




**Remission — small business**

**53** Subject to section 54, remission is granted to the person referred to in subsection 52(2) of an amount equal to 25% of the fee that is payable under subsection 52(1) if the person provides with the notification provided under subsection C.01.014.5(1) of the [Food and Drug Regulations](/en/Regulations/Consolidated%20Regulations%20of%20Canada/801-900/C.R.C.,%20c.%20870.md), in a form established by the Minister,
- **(a)** in the case where the person has completed their first fiscal year,
	- **(i)** a statement indicating that the person met the definition small business in subsection 1(1) in their last completed fiscal year, and
	- **(ii)** the following information:
		- **(A)** a list of the persons with which the person was affiliated in the person’s last completed fiscal year,
		- **(B)** the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person was affiliated in the person’s last completed fiscal year,
		- **(C)** the number of employees of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year, and
		- **(D)** the gross revenue of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year; and
- **(b)** in the case where the person has not completed their first fiscal year,
	- **(i)** a statement indicating that the person anticipates meeting the definition small business in subsection 1(1) in their first fiscal year, and
	- **(ii)** the following information:
		- **(A)** a list of the persons with which the person is affiliated in the person’s first fiscal year,
		- **(B)** the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person is affiliated in the person’s first fiscal year,
		- **(C)** the number of employees of the person in their first fiscal year and of the persons with which the person is affiliated in those persons’ last completed fiscal year, and
		- **(D)** the projected gross revenue of the person in their first fiscal year and the gross revenue of the persons with which the person is affiliated in those persons’ last completed fiscal year.




**Difference payable**

**54** If the Minister requests under section 5 that the person referred to in subsection 52(2) provide additional information, the difference between the fee payable under subsection 52(1) and the amount already paid is immediately payable if
- **(a)** the person has not provided, within the period specified in section 5, the Minister with additional information for the purpose of demonstrating that the person met the definition small business in subsection 1(1) in the applicable fiscal year; or
- **(b)** the person has provided, within the period specified in section 5, the Minister with additional information for the purpose of demonstrating that the person met the definition in the applicable fiscal year but the Minister determines, after the period ends, that the person has not provided sufficient information to demonstrate that they met that definition in the applicable fiscal year.




**DIVISION 5** 
### Fees for Right to Sell Drugs for Veterinary Use Only



#### Application



**Application**

**55** This Division applies to drug for veterinary use only.




#### Fees and Remission



**Annual fee**

**56** 

- **(1)** The annual fee that is payable for the right to sell a drug for which a drug identification number has been assigned under subsection C.01.014.2(1) of the [Food and Drug Regulations](/en/Regulations/Consolidated%20Regulations%20of%20Canada/801-900/C.R.C.,%20c.%20870.md) is as follows:
	- **(a)** in the case of a fee that is payable in a fiscal year set out in any of columns 1 to 4 of Schedule 7, the fee set out in that column; and
	- **(b)** in the case of a fee that is payable in a fiscal year other than one set out in any of columns 1 to 4 of Schedule 7, the amount that is calculated in accordance with subsection 4(2).

**Fee payable by person after first sale**

- **(2)** The fee is payable by the person to which a document was issued under subsection C.01.014.2(1) of the [Food and Drug Regulations](/en/Regulations/Consolidated%20Regulations%20of%20Canada/801-900/C.R.C.,%20c.%20870.md) that sets out the drug identification number assigned for the drug if the person has sold the drug following the issuance of the document.

**Timing of payment**

- **(3)** The fee is payable on October 1.

**Non-application — interruption of sale**

- **(4)** Subject to subsection (5), subsection (1) does not apply to the person if they notified the Minister in accordance with section C.01.014.71 of the [Food and Drug Regulations](/en/Regulations/Consolidated%20Regulations%20of%20Canada/801-900/C.R.C.,%20c.%20870.md) in the 12 months preceding October 1.

**Resumption of sale**

- **(5)** Subsection (4) ceases to apply on the day on which the person notifies the Minister in accordance with section C.01.014.72 of the [Food and Drug Regulations](/en/Regulations/Consolidated%20Regulations%20of%20Canada/801-900/C.R.C.,%20c.%20870.md).




**Remission — small business**

**57** Subject to section 58, remission is granted to the person referred to in subsection 56(2) of an amount equal to 25% of the fee that is payable under subsection 56(1) if the person provides with the notification provided under subsection C.01.014.5(1) of the [Food and Drug Regulations](/en/Regulations/Consolidated%20Regulations%20of%20Canada/801-900/C.R.C.,%20c.%20870.md), in a form established by the Minister,
- **(a)** in the case where the person has completed their first fiscal year,
	- **(i)** a statement indicating that the person met the definition small business in subsection 1(1) in their last completed fiscal year, and
	- **(ii)** the following information:
		- **(A)** a list of the persons with which the person was affiliated in the person’s last completed fiscal year,
		- **(B)** the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person was affiliated in the person’s last completed fiscal year,
		- **(C)** the number of employees of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year, and
		- **(D)** the gross revenue of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year; and
- **(b)** in the case where the person has not completed their first fiscal year,
	- **(i)** a statement indicating that the person anticipates meeting the definition small business in subsection 1(1) in their first fiscal year, and
	- **(ii)** the following information:
		- **(A)** a list of the persons with which the person is affiliated in the person’s first fiscal year,
		- **(B)** the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person is affiliated in the person’s first fiscal year,
		- **(C)** the number of employees of the person in their first fiscal year and of the persons with which the person is affiliated in those persons’ last completed fiscal year, and
		- **(D)** the projected gross revenue of the person in their first fiscal year and the gross revenue of the persons with which the person is affiliated in those persons’ last completed fiscal year.




**Difference payable**

**58** If the Minister requests under section 5 that the person referred to in subsection 56(2) provide additional information, the difference between the fee payable under subsection 56(1) and the amount already paid is immediately payable if
- **(a)** the person has not provided, within the period specified in section 5, the Minister with additional information for the purpose of demonstrating that the person met the definition small business in subsection 1(1) in the applicable fiscal year; or
- **(b)** the person has provided, within the period specified in section 5, the Minister with additional information for the purpose of demonstrating that the person met the definition in the applicable fiscal year but the Minister determines, after the period ends, that the person has not provided sufficient information to demonstrate that they met that definition in the applicable fiscal year.




**PART 3** 
## Medical Devices



**DIVISION 1** 
### Fees for Examination of an Application for a Medical Device Licence



#### Interpretation



**Definition of licence**

**59** In this Division, ***licence*** means a medical device licence issued under paragraph 36(1)(a) of the [Medical Devices Regulations](/en/Regulations/Statutory%20Orders%20and%20Regulations/98/282.md).




#### Fees and Remissions



**Fee for examination**

**60** 

- **(1)** Subject to paragraph 62(b) and section 64, the fee for the examination of an application for a licence that is filed under section 32 of the [Medical Devices Regulations](/en/Regulations/Statutory%20Orders%20and%20Regulations/98/282.md) or for the examination of an application for a licence amendment that is filed under section 34 of those Regulations is, in respect of the applicable category set out in column 1 of Schedule 8 and described in column 2, as follows:
	- **(a)** in the case of a fee that is payable in a fiscal year set out in any of columns 3 to 6 of Schedule 8, the fee set out in that column; and
	- **(b)** in the case of a fee that is payable in a fiscal year other than one set out in any of columns 3 to 6 of Schedule 8, the amount that is calculated in accordance with subsection 4(2).

**Fee payable by person that files application**

- **(2)** The fee is payable by the person that files the application.




**Reinstatement**

**61** Every provision of this Division that applies to an application for a licence for a Class II, III or IV medical device filed under section 32 of the [Medical Devices Regulations](/en/Regulations/Statutory%20Orders%20and%20Regulations/98/282.md) also applies to a request to have such a licence reinstated following the correction of the situation that gave rise to its suspension.




**Fee and timing of payment — preliminary examination**

**62** If a preliminary examination is conducted in respect of an application,
- **(a)** the full fee is payable on the issuance by the Minister of a notice to the person referred to in subsection 60(2) stating that the application has been found to be complete and has been accepted for further examination; or
- **(b)** 10% of the fee is payable on the issuance by the Minister of a notice to the person referred to in subsection 60(2) stating that the application has been found to be incomplete.




**Fee and timing of payment — no preliminary examination**

**63** If a preliminary examination is not conducted in respect of an application, the fee is payable on the issuance by the Minister of a notice to the person referred to in subsection 60(2) stating that the application has been received.




**Fee — filing in previous fiscal year**

**64** For the purposes of subsection 60(1), if the Minister issues a notice referred to in section 62 or 63 in the fiscal year that follows the fiscal year in which the application was filed, the fee that is payable is the fee that was payable in the fiscal year in which the application was filed.




**Remission — General Council Decision**

**65** Remission is granted to the person referred to in subsection 60(2) of an amount equal to the fee that is payable under subsection 60(1) if the person has received an authorization under section 21.04 of the [Patent Act](/en/Acts/Revised%20Statutes%20of%20Canada/P/P-4.md) in respect of the medical device.




**Remission — small business**

**66** Subject to section 68, remission is granted to the person referred to in subsection 60(2) of an amount equal to 50% of the fee that is payable under subsection 60(1) if the person provides with their application, in a form established by the Minister,
- **(a)** in the case where the person has completed their first fiscal year,
	- **(i)** a statement indicating that the person met the definition small business in subsection 1(1) in their last completed fiscal year, and
	- **(ii)** the following information:
		- **(A)** a list of the persons with which the person was affiliated in the person’s last completed fiscal year,
		- **(B)** the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person was affiliated in the person’s last completed fiscal year,
		- **(C)** the number of employees of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year, and
		- **(D)** the gross revenue of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year; and
- **(b)** in the case where the person has not completed their first fiscal year,
	- **(i)** a statement indicating that the person anticipates meeting the definition small business in subsection 1(1) in their first fiscal year, and
	- **(ii)** the following information:
		- **(A)** a list of the persons with which the person is affiliated in the person’s first fiscal year,
		- **(B)** the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person is affiliated in the person’s first fiscal year,
		- **(C)** the number of employees of the person in their first fiscal year and of the persons with which the person is affiliated in those persons’ last completed fiscal year, and
		- **(D)** the projected gross revenue of the person in their first fiscal year and the gross revenue of the persons with which the person is affiliated in those persons’ last completed fiscal year.




**Remission — first application by small business**

**67** Subject to section 68, remission is granted to the person referred to in subsection 60(2) of an amount equal to the fee that is payable under subsection 60(1) if the following conditions are met:
- **(a)** the person has not previously filed an application for a licence under section 32 of the [Medical Devices Regulations](/en/Regulations/Statutory%20Orders%20and%20Regulations/98/282.md); and
- **(b)** the person provides with their application, in a form established by the Minister,
	- **(i)** in the case where the person has completed their first fiscal year,
		- **(A)** a statement indicating that the person met the definition small business in subsection 1(1) in their last completed fiscal year, and
		- **(B)** the following information:
			- **(I)** a list of the persons with which the person was affiliated in the person’s last completed fiscal year,
			- **(II)** the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person was affiliated in the person’s last completed fiscal year,
			- **(III)** the number of employees of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year, and
			- **(IV)** the gross revenue of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year, and
	- **(ii)** in the case where the person has not completed their first fiscal year,
		- **(A)** a statement indicating that the person anticipates meeting the definition small business in subsection 1(1) in their first fiscal year, and
		- **(B)** the following information:
			- **(I)** a list of the persons with which the person is affiliated in the person’s first fiscal year,
			- **(II)** the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person is affiliated in the person’s first fiscal year,
			- **(III)** the number of employees of the person in their first fiscal year and of the persons with which the person is affiliated in those persons’ last completed fiscal year, and
			- **(IV)** the projected gross revenue of the person in their first fiscal year and the gross revenue of the persons with which the person is affiliated in those persons’ last completed fiscal year.




**Fee or difference payable**

**68** If the Minister requests under section 5 that the person referred to in subsection 60(2) provide additional information, the fee — or the difference between the fee payable under subsection 60(1) and the amount already paid, as the case may be — is immediately payable if
- **(a)** the person has not provided, within the period specified in section 5, the Minister with additional information for the purpose of demonstrating that the person met the definition small business in subsection 1(1) in the applicable fiscal year; or
- **(b)** the person has provided, within the period specified in section 5, the Minister with additional information for the purpose of demonstrating that the person met the definition in the applicable fiscal year but the Minister determines, after the period ends, that the person has not provided sufficient information to demonstrate that they met that definition in the applicable fiscal year.




**DIVISION 2** 
### Fees for Examination of an Application for an Establishment Licence — Medical Devices



#### Interpretation



**Definition of establishment licence**

**69** In this Division, ***establishment licence*** means a licence issued under section 46 of the [Medical Devices Regulations](/en/Regulations/Statutory%20Orders%20and%20Regulations/98/282.md).




#### Application



**Applicable classes**

**70** This Division applies to persons that import or sell medical devices that are subject to the [Medical Devices Regulations](/en/Regulations/Statutory%20Orders%20and%20Regulations/98/282.md), other than persons that import or sell only medical devices that are subject to Part 2 or 3 of those Regulations.




#### Fee and Remission



**Fee for examination**

**71** 

- **(1)** The fee that is payable for the examination of an application for an establishment licence filed under section 45 of the [Medical Devices Regulations](/en/Regulations/Statutory%20Orders%20and%20Regulations/98/282.md) or for the annual review of such a licence filed under section 46.1 of those Regulations is $4,590.

**Fee paid by person that files application**

- **(2)** The fee is payable by the person that files the application.




**Timing of payment**

**72** The fee is payable on the issuance by the Minister of a notice to the person referred to in subsection 71(2) stating that the application has been accepted for further examination.




**Reinstatement**

**73** Every provision of this Division that applies to an application for an establishment licence also applies to a request to have such a licence reinstated following the correction of the situation that gave rise to its suspension.




**Remission — small business**

**74** Subject to section 75, remission is granted to the person referred to in subsection 71(2) of an amount equal to 25% of the fee that is payable under subsection 71(1) if the person provides with their application, in a form established by the Minister,
- **(a)** in the case where the person has completed their first fiscal year,
	- **(i)** a statement indicating that the person met the definition small business in subsection 1(1) in their last completed fiscal year, and
	- **(ii)** the following information:
		- **(A)** a list of the persons with which the person was affiliated in the person’s last completed fiscal year,
		- **(B)** the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person was affiliated in the person’s last completed fiscal year,
		- **(C)** the number of employees of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year, and
		- **(D)** the gross revenue of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year; and
- **(b)** in the case where the person has not completed their first fiscal year,
	- **(i)** a statement indicating that the person anticipates meeting the definition small business in subsection 1(1) in their first fiscal year, and
	- **(ii)** the following information:
		- **(A)** a list of the persons with which the person is affiliated in the person’s first fiscal year,
		- **(B)** the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person is affiliated in the person’s first fiscal year,
		- **(C)** the number of employees of the person in their first fiscal year and of the persons with which the person is affiliated in those persons’ last completed fiscal year, and
		- **(D)** the projected gross revenue of the person in their first fiscal year and the gross revenue of the persons with which the person is affiliated in those persons’ last completed fiscal year.




**Difference payable**

**75** If the Minister requests under section 5 that the person referred to in subsection 71(2) provide additional information, the difference between the fee payable under subsection 71(1) and the amount already paid is immediately payable if
- **(a)** the person has not provided, within the period specified in section 5, the Minister with additional information for the purpose of demonstrating that the person met the definition small business in subsection 1(1) in the applicable fiscal year; or
- **(b)** the person has provided, within the period specified in section 5, the Minister with additional information for the purpose of demonstrating that the person met the definition in the applicable fiscal year but the Minister determines, after the period ends, that the person has not provided sufficient information to demonstrate that they met that definition in the applicable fiscal year.




**DIVISION 3** 
### Fees for Right to Sell Licensed Class II, III or IV Medical Devices



#### Interpretation



**Definition of licence**

**76** In this Division, ***licence*** means a medical device licence issued under paragraph 36(1)(a) of the [Medical Devices Regulations](/en/Regulations/Statutory%20Orders%20and%20Regulations/98/282.md).




#### Fees and Remission



**Annual fee**

**77** 

- **(1)** The annual fee that is payable for the right to sell a licensed Class II, III or IV medical device is $381.

**Fee payable by holder — licence not suspended**

- **(2)** The fee is payable by the person that holds the licence for the Class II, III or IV medical device if the licence is not suspended under section 40 or 41 of the [Medical Devices Regulations](/en/Regulations/Statutory%20Orders%20and%20Regulations/98/282.md).




**Timing of payment**

**78** The fee is payable on December 20.




**Remission — small business**

**79** Subject to section 80, remission is granted to the person referred to in subsection 77(2) of an amount equal to 25% of the fee that is payable under subsection 77(1) if the person provides with the statement provided under subsection 43(1) of the [Medical Devices Regulations](/en/Regulations/Statutory%20Orders%20and%20Regulations/98/282.md), in a form established by the Minister,
- **(a)** in the case where the person has completed their first fiscal year,
	- **(i)** a statement indicating that the person met the definition small business in subsection 1(1) in their last completed fiscal year, and
	- **(ii)** the following information:
		- **(A)** a list of the persons with which the person was affiliated in the person’s last completed fiscal year,
		- **(B)** the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person was affiliated in the person’s last completed fiscal year,
		- **(C)** the number of employees of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year, and
		- **(D)** the gross revenue of the person in their last fiscal year and of the persons with which the person was affiliated in those persons’ last completed fiscal year; and
- **(b)** in the case where the person has not completed their first fiscal year,
	- **(i)** a statement indicating that the person anticipates meeting the definition small business in subsection 1(1) in their first fiscal year, and
	- **(ii)** the following information:
		- **(A)** a list of the persons with which the person is affiliated in the person’s first fiscal year,
		- **(B)** the start and end dates of the person’s fiscal year and of the fiscal year of the persons with which the person is affiliated in the person’s first fiscal year,
		- **(C)** the number of employees of the person in their first fiscal year and of the persons with which the person is affiliated in those persons’ last completed fiscal year, and
		- **(D)** the projected gross revenue of the person in their first fiscal year and the gross revenue of the persons with which the person is affiliated in those persons’ last completed fiscal year.




**Difference payable**

**80** If the Minister requests under section 5 that the person referred to in subsection 77(2) provide additional information, the difference between the fee payable under subsection 77(1) and the amount already paid is immediately payable if
- **(a)** the person has not provided, within the period specified in section 5, the Minister with additional information for the purpose of demonstrating that the person met the definition small business in subsection 1(1) in the applicable fiscal year; or
- **(b)** the person has provided, within the period specified in section 5, the Minister with additional information for the purpose of demonstrating that the person met the definition in the applicable fiscal year but the Minister determines, after the period ends, that the person has not provided sufficient information to demonstrate that they met that definition in the applicable fiscal year.




## Coming into Force



**SOR/96-143**

<sup><a href='#fn_SOR-2019-124_e_transform_hq_25134'>[*]</a></sup>**81** This Order comes into force on the day on which the [Veterinary Drug Evaluation Fees Regulations](/en/Regulations/Statutory%20Orders%20and%20Regulations/96/143.md) are repealed but if it is registered after that day, it comes into force on the day on which it is registered.

<a name='fn_SOR-2019-124_e_transform_hq_25134'><sup>*</sup></a>: [Note: Regulations in force April 1, 2020.]<br />




### **SCHEDULE 1** 
**(Section 9)**
<table>
<h4>Fees for Examination of a Submission — Drugs for Human Use</h4>
<tr>
<th>Item</th>
<th>Column 1</th>
<th>Column 2</th>
<th>Column 3</th>
<th>Column 4</th>
<th>Column 5</th>
<th>Column 6</th>
</tr>
<tr>
<th>Submission Class</th>
<th>Description</th>
<th>Fee ($)</th>
<th>Fee ($)</th>
<th>Fee ($)</th>
<th>Fee ($)</th>
</tr>
<tr>
<th>Fiscal Year</th>
<th>Fiscal Year</th>
<th>Fiscal Year</th>
<th>Fiscal Year</th>
</tr>
<tr>
<th>2020-2021</th>
<th>2021-2022</th>
<th>2022-2023</th>
<th>2023-2024</th>
</tr>
<tr>
<td>1</td>
<td>New active substance</td>
<td>Submissions in support of a drug, other than a disinfectant, that contains a medicinal ingredient not previously approved in a drug for sale in Canada and that is not a variation of a previously approved medicinal ingredient such as a salt, ester, enantiomer, solvate or polymorph</td>
<td>400,288</td>
<td>437,884</td>
<td>475,481</td>
<td>513,077</td>
</tr>
<tr>
<td>2</td>
<td>Clinical or non-clinical data and chemistry and manufacturing data</td>
<td>Submissions based on clinical or non-clinical data and chemistry and manufacturing data for a drug that does not include a new active substance</td>
<td>204,197</td>
<td>224,691</td>
<td>245,185</td>
<td>265,678</td>
</tr>
<tr>
<td>3</td>
<td>Clinical or non-clinical data only</td>
<td>Submissions based only on clinical or non-clinical data for a drug that does not include a new active substance</td>
<td>90,864</td>
<td>95,987</td>
<td>101,110</td>
<td>106,232</td>
</tr>
<tr>
<td>4</td>
<td>Comparative studies</td>
<td>Submissions based on comparative studies (e.g., clinical or non-clinical data, bioavailability data and data on the pharmacokinetics and pharmacodynamics of the drug) with or without chemistry and manufacturing data for a drug that does not include a new active substance</td>
<td>53,836</td>
<td>55,848</td>
<td>57,859</td>
<td>59,870</td>
</tr>
<tr>
<td>5</td>
<td>Chemistry and manufacturing data only</td>
<td>Submissions based only on chemistry and manufacturing data for a drug that does not include a new active substance</td>
<td>27,587</td>
<td>30,670</td>
<td>33,752</td>
<td>36,835</td>
</tr>
<tr>
<td>6</td>
<td>Clinical or non-clinical data only, in support of safety updates to the labelling</td>
<td>Submissions based only on clinical or non-clinical data, in support of safety updates to the labelling materials for a new drug that does not include a new active substance</td>
<td>19,442</td>
<td>19,442</td>
<td>19,442</td>
<td>19,442</td>
</tr>
<tr>
<td>7</td>
<td>Labelling only</td>
<td>Submissions, other than those described in item 8, 11 or 12, of labelling material, that include data in support of the following: brand name assessment, standardized or published test methods, in vitro or in vivo photostability or applications for a drug identification number in support of changes to brand names of non-prescription drugs (but not including examination of other supporting clinical or non-clinical data, comparative data, or chemistry and manufacturing data)</td>
<td>3,816</td>
<td>4,328</td>
<td>4,841</td>
<td>5,353</td>
</tr>
<tr>
<td>8</td>
<td>Labelling only (generic drugs)</td>
<td>Submissions in support of a change to the labelling to be consistent with the Canadian reference product that do not include any additional labelling updates requiring a labelling assessment</td>
<td>2,010</td>
<td>2,010</td>
<td>2,010</td>
<td>2,010</td>
</tr>
<tr>
<td>9</td>
<td>Administrative submission</td>
<td>Submissions in support of a change in the manufacturer’s name or brand name, including the following: changes in ownership of the drug, request for an additional brand name or changes resulting from a licensing agreement being entered into by two manufacturers that do not require an assessment of labelling material or brand name (e.g., post-authorization label changes filed by licensees to remain identical to licensor’s drug and post-authorization chemistry and manufacturing updates for drugs listed in Schedule C or D of the [Food and Drugs Act](/en/Acts/Revised%20Statutes%20of%20Canada/F/F-27.md))</td>
<td>432</td>
<td>540</td>
<td>676</td>
<td>845</td>
</tr>
<tr>
<td>10</td>
<td>Disinfectant — full review</td>
<td>Submissions, other than those described in item 11, that include data in support of a disinfectant</td>
<td>5,712</td>
<td>7,140</td>
<td>8,925</td>
<td>11,157</td>
</tr>
<tr>
<td>11</td>
<td>Labelling only (disinfectants)</td>
<td>Submissions in support of changes to the labelling of disinfectants that do not require supporting data, submissions in support of safety updates for disinfectants that are new drugs or submissions in support of a change in the manufacturer’s name or brand name that requires a review of labelling material due to deviations from the previously authorized labelling or drug</td>
<td>2,507</td>
<td>2,507</td>
<td>2,507</td>
<td>2,507</td>
</tr>
<tr>
<td>12</td>
<td>Drug identification number application — labelling standards</td>
<td>Applications, including those that pertain to changes to brand names for non-prescription drugs, that include an attestation of compliance with a labelling standard or Category IV Monograph for a drug and that do not include clinical or non-clinical data or chemistry and manufacturing data</td>
<td>1,616</td>
<td>1,616</td>
<td>1,616</td>
<td>1,616</td>
</tr>
</table>




### **SCHEDULE 2** 
**(Section 21)**
<table>
<h4>Fees for Examination of a Submission — Drugs for Veterinary Use Only</h4>
<tr>
<th>Item</th>
<th>Column 1</th>
<th>Column 2</th>
<th>Column 3</th>
<th>Column 4</th>
<th>Column 5</th>
<th>Column 6</th>
<th>Column 7</th>
<th>Column 8</th>
<th>Column 9</th>
</tr>
<tr>
<th>Type of Submission</th>
<th>Component</th>
<th>Fee ($)</th>
<th>Fee ($)</th>
<th>Fee ($)</th>
<th>Fee ($)</th>
<th>Fee ($)</th>
<th>Fee ($)</th>
<th>Fee ($)</th>
</tr>
<tr>
<th>Fiscal Year</th>
<th>Fiscal Year</th>
<th>Fiscal Year</th>
<th>Fiscal Year</th>
<th>Fiscal Year</th>
<th>Fiscal Year</th>
<th>Fiscal Year</th>
</tr>
<tr>
<th>2020-2021</th>
<th>2021-2022</th>
<th>2022-2023</th>
<th>2023-2024</th>
<th>2024-2025</th>
<th>2025-2026</th>
<th>2026-2027</th>
</tr>
<tr>
<td>1</td>
<td>Application for drug identification number</td>
<td>Information, other than that referred to in item 2, to support an application for a drug identification number, including the submission of labelling material for a second review, if required</td>
<td>918</td>
<td>1,148</td>
<td>1,436</td>
<td>1,714</td>
<td>1,959</td>
<td>2,204</td>
<td>2,448</td>
</tr>
<tr>
<td>2</td>
<td>Application for drug identification number</td>
<td>Published references or other data</td>
<td>638</td>
<td>798</td>
<td>998</td>
<td>1,191</td>
<td>1,361</td>
<td>1,532</td>
<td>1,701</td>
</tr>
<tr>
<td>3</td>
<td>Application for drug identification number</td>
<td>Documentation to support a change of manufacturer, a change to the name of a manufacturer or a change to the brand name of a drug<sup><a href='#fn_1'>[1]</a></sup></td>
<td>320</td>
<td>400</td>
<td>500</td>
<td>596</td>
<td>681</td>
<td>765</td>
<td>850</td>
</tr>
<tr>
<td>4</td>
<td>Notification — veterinary health product</td>
<td>Information contained in a notification filed under subsection C.01.615(1) of the [Food and Drug Regulations](/en/Regulations/Consolidated%20Regulations%20of%20Canada/801-900/C.R.C.,%20c.%20870.md) in respect of a veterinary health product</td>
<td>486</td>
<td>486</td>
<td>486</td>
<td>486</td>
<td>486</td>
<td>486</td>
<td>486</td>
</tr>
<tr>
<td>5</td>
<td>New drug submission</td>
<td>Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in one animal species (in the case of an antiparasitic drug, several indications in one food animal species)</td>
<td>20,375</td>
<td>25,469</td>
<td>31,837</td>
<td>38,033</td>
<td>43,467</td>
<td>48,900</td>
<td>54,333</td>
</tr>
<tr>
<td>6</td>
<td>New drug submission</td>
<td>Efficacy and safety data (in the intended species) to support a single route of administration and dosage form for an antiparasitic drug in one non-food animal species</td>
<td>12,342</td>
<td>15,428</td>
<td>19,286</td>
<td>23,039</td>
<td>26,331</td>
<td>29,622</td>
<td>32,913</td>
</tr>
<tr>
<td>7</td>
<td>New drug submission</td>
<td>Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in two animal species, or a single route of administration and dosage form and two indications in one animal species</td>
<td>29,631</td>
<td>37,040</td>
<td>46,300</td>
<td>55,312</td>
<td>63,214</td>
<td>71,116</td>
<td>79,017</td>
</tr>
<tr>
<td>8</td>
<td>New drug submission</td>
<td>Efficacy and safety data (in the intended species) to support a growth promotion or production enhancement indication in one animal species</td>
<td>40,125</td>
<td>50,157</td>
<td>62,697</td>
<td>74,899</td>
<td>85,599</td>
<td>96,299</td>
<td>106,998</td>
</tr>
<tr>
<td>9</td>
<td>New drug submission</td>
<td>Comparative (pharmacodynamic, clinical or bioavailability) data to support an additional route of administration</td>
<td>3,698</td>
<td>4,623</td>
<td>5,779</td>
<td>6,903</td>
<td>7,889</td>
<td>8,876</td>
<td>9,861</td>
</tr>
<tr>
<td>10</td>
<td>New drug submission</td>
<td>Comparative (pharmacodynamic, clinical or bioavailability) data to support each additional strength</td>
<td>612</td>
<td>765</td>
<td>957</td>
<td>1,143</td>
<td>1,306</td>
<td>1,469</td>
<td>1,632</td>
</tr>
<tr>
<td>11</td>
<td>New drug submission</td>
<td>For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of 1,000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species</td>
<td>27,783</td>
<td>34,729</td>
<td>43,412</td>
<td>51,861</td>
<td>59,270</td>
<td>66,678</td>
<td>74,086</td>
</tr>
<tr>
<td>12</td>
<td>New drug submission</td>
<td>For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of less than 1,000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species</td>
<td>37,040</td>
<td>46,300</td>
<td>57,875</td>
<td>69,140</td>
<td>79,017</td>
<td>88,893</td>
<td>98,770</td>
</tr>
<tr>
<td>13</td>
<td>New drug submission</td>
<td>For food-producing animals, residue depletion studies to establish a withdrawal period for an additional dosage form, dosage or route of administration</td>
<td>3,698</td>
<td>4,623</td>
<td>5,779</td>
<td>6,903</td>
<td>7,889</td>
<td>8,876</td>
<td>9,861</td>
</tr>
<tr>
<td>14</td>
<td>New drug submission</td>
<td>For food-producing animals (once an acceptable daily intake with a safety factor of 1,000 or less has been established), metabolism and residue depletion studies to establish a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in an additional species</td>
<td>18,513</td>
<td>23,142</td>
<td>28,928</td>
<td>34,558</td>
<td>39,495</td>
<td>44,432</td>
<td>49,368</td>
</tr>
<tr>
<td>15</td>
<td>New drug submission</td>
<td>Chemistry and manufacturing data for a non-compendial medicinal ingredient of a drug</td>
<td>6,171</td>
<td>7,715</td>
<td>9,644</td>
<td>11,520</td>
<td>13,166</td>
<td>14,811</td>
<td>16,456</td>
</tr>
<tr>
<td>16</td>
<td>New drug submission</td>
<td>Chemistry and manufacturing data to support one strength of a single dosage form</td>
<td>6,171</td>
<td>7,715</td>
<td>9,644</td>
<td>11,520</td>
<td>13,166</td>
<td>14,811</td>
<td>16,456</td>
</tr>
<tr>
<td>17</td>
<td>New drug submission</td>
<td>Chemistry and manufacturing data to support an additional strength of a single dosage form submitted at the same time as item 16</td>
<td>3,086</td>
<td>3,858</td>
<td>4,823</td>
<td>5,760</td>
<td>6,584</td>
<td>7,407</td>
<td>8,229</td>
</tr>
<tr>
<td>18</td>
<td>New drug submission</td>
<td>Documentation to support a change of manufacturer<sup><a href='#fn_2'>[2]</a></sup></td>
<td>320</td>
<td>400</td>
<td>500</td>
<td>596</td>
<td>681</td>
<td>765</td>
<td>850</td>
</tr>
<tr>
<td>19</td>
<td>Supplement to a new drug submission</td>
<td>Efficacy data to support an additional indication in one animal species</td>
<td>16,053</td>
<td>20,067</td>
<td>25,084</td>
<td>29,965</td>
<td>34,246</td>
<td>38,527</td>
<td>42,807</td>
</tr>
<tr>
<td>20</td>
<td>Supplement to a new drug submission</td>
<td>Efficacy and safety data (in the intended species) to support a single route of administration and dosage form for an antiparasitic drug in one non-food animal species</td>
<td>12,342</td>
<td>15,428</td>
<td>19,286</td>
<td>23,039</td>
<td>26,331</td>
<td>29,622</td>
<td>32,913</td>
</tr>
<tr>
<td>21</td>
<td>Supplement to a new drug submission</td>
<td>Efficacy and safety data (in the intended species) to support an indication in another animal species</td>
<td>20,375</td>
<td>25,469</td>
<td>31,837</td>
<td>38,033</td>
<td>43,467</td>
<td>48,900</td>
<td>54,333</td>
</tr>
<tr>
<td>22</td>
<td>Supplement to a new drug submission</td>
<td>Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in two animal species, or a single route of administration and dosage form and two indications in one animal species</td>
<td>29,631</td>
<td>37,040</td>
<td>46,300</td>
<td>55,312</td>
<td>63,214</td>
<td>71,116</td>
<td>79,017</td>
</tr>
<tr>
<td>23</td>
<td>Supplement to a new drug submission</td>
<td>Efficacy and safety data (in the intended species) to support a growth promotion or production enhancement indication in one animal species</td>
<td>40,125</td>
<td>50,157</td>
<td>62,697</td>
<td>74,899</td>
<td>85,599</td>
<td>96,299</td>
<td>106,998</td>
</tr>
<tr>
<td>24</td>
<td>Supplement to a new drug submission</td>
<td>Efficacy and safety data (in the intended species) to support the concurrent use of two drugs approved for the same animal species</td>
<td>9,869</td>
<td>12,336</td>
<td>15,421</td>
<td>18,422</td>
<td>21,053</td>
<td>23,685</td>
<td>26,316</td>
</tr>
<tr>
<td>25</td>
<td>Supplement to a new drug submission</td>
<td>Comparative (pharmacodynamic, clinical or bioavailability) data to support an additional route of administration</td>
<td>3,698</td>
<td>4,623</td>
<td>5,779</td>
<td>6,903</td>
<td>7,889</td>
<td>8,876</td>
<td>9,861</td>
</tr>
<tr>
<td>26</td>
<td>Supplement to a new drug submission</td>
<td>Comparative (pharmacodynamic, clinical or bioavailability) data to support each additional strength</td>
<td>612</td>
<td>765</td>
<td>957</td>
<td>1,143</td>
<td>1,306</td>
<td>1,469</td>
<td>1,632</td>
</tr>
<tr>
<td>27</td>
<td>Supplement to a new drug submission</td>
<td>For food-producing animals, residue depletion studies to establish a new withdrawal period for a change in the dosage or route of administration of an approved dosage form in one species</td>
<td>3,698</td>
<td>4,623</td>
<td>5,779</td>
<td>6,903</td>
<td>7,889</td>
<td>8,876</td>
<td>9,861</td>
</tr>
<tr>
<td>28</td>
<td>Supplement to a new drug submission</td>
<td>For food-producing animals, metabolism and residue depletion studies to establish a maximum residue limit and a withdrawal period for a single dosage and route of administration of an approved dosage form in an additional species</td>
<td>18,513</td>
<td>23,142</td>
<td>28,928</td>
<td>34,558</td>
<td>39,495</td>
<td>44,432</td>
<td>49,368</td>
</tr>
<tr>
<td>29</td>
<td>Supplement to a new drug submission</td>
<td>For food-producing animals, toxicity studies to support a change of an established acceptable daily intake, a maximum residue limit and a withdrawal period</td>
<td>9,257</td>
<td>11,571</td>
<td>14,464</td>
<td>17,279</td>
<td>19,748</td>
<td>22,216</td>
<td>24,684</td>
</tr>
<tr>
<td>30</td>
<td>Supplement to a new drug submission</td>
<td>For the concurrent use of two drugs in a species of food-producing animals, residue depletion studies to determine if an extension to existing withdrawal periods is required</td>
<td>7,409</td>
<td>9,261</td>
<td>11,576</td>
<td>13,829</td>
<td>15,804</td>
<td>17,780</td>
<td>19,755</td>
</tr>
<tr>
<td>31</td>
<td>Supplement to a new drug submission</td>
<td>Chemistry and manufacturing data to support a change in the source of a medicinal ingredient or its manufacturing process</td>
<td>6,171</td>
<td>7,715</td>
<td>9,644</td>
<td>11,520</td>
<td>13,166</td>
<td>14,811</td>
<td>16,456</td>
</tr>
<tr>
<td>32</td>
<td>Supplement to a new drug submission</td>
<td>Chemistry and manufacturing data to support a change in formulation or dosage form</td>
<td>3,086</td>
<td>3,858</td>
<td>4,823</td>
<td>5,760</td>
<td>6,584</td>
<td>7,407</td>
<td>8,229</td>
</tr>
<tr>
<td>33</td>
<td>Supplement to a new drug submission</td>
<td>Chemistry and manufacturing data to support a change in the packaging or sterilization process</td>
<td>2,462</td>
<td>3,078</td>
<td>3,848</td>
<td>4,595</td>
<td>5,250</td>
<td>5,906</td>
<td>6,562</td>
</tr>
<tr>
<td>34</td>
<td>Supplement to a new drug submission</td>
<td>Chemistry and manufacturing data to support an extension of the expiry date</td>
<td>1,850</td>
<td>2,313</td>
<td>2,891</td>
<td>3,452</td>
<td>3,945</td>
<td>4,437</td>
<td>4,930</td>
</tr>
<tr>
<td>35</td>
<td>Supplement to a new drug submission</td>
<td>Chemistry and manufacturing data to support the concurrent use of two drugs</td>
<td>1,850</td>
<td>2,313</td>
<td>2,891</td>
<td>3,452</td>
<td>3,945</td>
<td>4,437</td>
<td>4,930</td>
</tr>
<tr>
<td>36</td>
<td>Supplement to a new drug submission</td>
<td>Chemistry and manufacturing data to support a change in the manufacturing site for parenteral dosage form</td>
<td>612</td>
<td>765</td>
<td>957</td>
<td>1,143</td>
<td>1,306</td>
<td>1,469</td>
<td>1,632</td>
</tr>
<tr>
<td>37</td>
<td>Supplement to a new drug submission</td>
<td>Documentation to support a change to the brand name of a drug<sup><a href='#fn_3'>[3]</a></sup></td>
<td>320</td>
<td>400</td>
<td>500</td>
<td>596</td>
<td>681</td>
<td>765</td>
<td>850</td>
</tr>
<tr>
<td>38</td>
<td>Abbreviated new drug submission or supplement to an abbreviated new drug submission</td>
<td>Comparative (pharmacodynamic, clinical or bioavailability) data to support a single route of administration and dosage form</td>
<td>3,698</td>
<td>4,623</td>
<td>5,779</td>
<td>6,903</td>
<td>7,889</td>
<td>8,876</td>
<td>9,861</td>
</tr>
<tr>
<td>39</td>
<td>Abbreviated new drug submission or supplement to an abbreviated new drug submission</td>
<td>For food-producing animals, residue depletion studies to confirm that the withdrawal periods for each species fall within the conditions of use for the Canadian reference product</td>
<td>3,698</td>
<td>4,623</td>
<td>5,779</td>
<td>6,903</td>
<td>7,889</td>
<td>8,876</td>
<td>9,861</td>
</tr>
<tr>
<td>40</td>
<td>Abbreviated new drug submission or supplement to an abbreviated new drug submission</td>
<td>Chemistry and manufacturing data for a non-compendial medicinal ingredient of a drug</td>
<td>6,171</td>
<td>7,715</td>
<td>9,644</td>
<td>11,520</td>
<td>13,166</td>
<td>14,811</td>
<td>16,456</td>
</tr>
<tr>
<td>41</td>
<td>Abbreviated new drug submission or supplement to an abbreviated new drug submission</td>
<td>Chemistry and manufacturing data to support a single dosage form</td>
<td>6,171</td>
<td>7,715</td>
<td>9,644</td>
<td>11,520</td>
<td>13,166</td>
<td>14,811</td>
<td>16,456</td>
</tr>
<tr>
<td>42</td>
<td>Abbreviated new drug submission or supplement to an abbreviated new drug submission</td>
<td>Documentation to support

**(a)** a change of manufacturer, in the case of an abbreviated new drug submission; or



**(b)** a change to the brand name of a drug, in the case of a supplement to an abbreviated new drug submission<sup><a href='#fn_4'>[4]</a></sup>



</td>
<td>320</td>
<td>400</td>
<td>500</td>
<td>596</td>
<td>681</td>
<td>765</td>
<td>850</td>
</tr>
<tr>
<td>43</td>
<td>Preclinical submission</td>
<td>Efficacy and safety data (in the intended species) and protocol to support the conduct of clinical studies relative to a single dosage form, route of administration and indication in one species</td>
<td>6,171</td>
<td>7,715</td>
<td>9,644</td>
<td>11,520</td>
<td>13,166</td>
<td>14,811</td>
<td>16,456</td>
</tr>
<tr>
<td>44</td>
<td>Preclinical submission</td>
<td>Efficacy data and protocol to support the conduct of clinical studies relative to a single route of administration and indication with a dosage form for which a notice of compliance has been issued for use in the species to be treated</td>
<td>4,935</td>
<td>6,169</td>
<td>7,712</td>
<td>9,211</td>
<td>10,527</td>
<td>11,843</td>
<td>13,158</td>
</tr>
<tr>
<td>45</td>
<td>Preclinical submission</td>
<td>For food-producing animals, toxicity, metabolism and residue depletion studies to establish a temporary acceptable daily intake, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species</td>
<td>18,513</td>
<td>23,142</td>
<td>28,928</td>
<td>34,558</td>
<td>39,495</td>
<td>44,432</td>
<td>49,368</td>
</tr>
<tr>
<td>46</td>
<td>Preclinical submission</td>
<td>For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of 1,000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species</td>
<td>27,783</td>
<td>34,729</td>
<td>43,412</td>
<td>51,861</td>
<td>59,270</td>
<td>66,678</td>
<td>74,086</td>
</tr>
<tr>
<td>47</td>
<td>Preclinical submission</td>
<td>For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of less than 1,000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species</td>
<td>37,040</td>
<td>46,300</td>
<td>57,875</td>
<td>69,140</td>
<td>79,017</td>
<td>88,893</td>
<td>98,770</td>
</tr>
<tr>
<td>48</td>
<td>Preclinical submission</td>
<td>For food-producing animals (once an acceptable daily intake with a safety factor of 1,000 or less has been established), metabolism studies to establish a withdrawal period for a single dosage form, dosage and route of administration in an additional species</td>
<td>9,257</td>
<td>11,571</td>
<td>14,464</td>
<td>17,279</td>
<td>19,748</td>
<td>22,216</td>
<td>24,684</td>
</tr>
<tr>
<td>49</td>
<td>Preclinical submission</td>
<td>Chemistry and manufacturing data to support a single dosage form containing a non-compendial medicinal ingredient</td>
<td>6,171</td>
<td>7,715</td>
<td>9,644</td>
<td>11,520</td>
<td>13,166</td>
<td>14,811</td>
<td>16,456</td>
</tr>
<tr>
<td>50</td>
<td>Preclinical submission</td>
<td>Chemistry and manufacturing data to support a single dosage form containing a compendial medicinal ingredient</td>
<td>3,086</td>
<td>3,858</td>
<td>4,823</td>
<td>5,760</td>
<td>6,584</td>
<td>7,407</td>
<td>8,229</td>
</tr>
<tr>
<td>51</td>
<td>Sale of new drug for emergency treatment</td>
<td>Information and material to support the sale of a new drug to be used in the emergency treatment of a non-food-producing animal</td>
<td>51</td>
<td>51</td>
<td>51</td>
<td>51</td>
<td>51</td>
<td>51</td>
<td>51</td>
</tr>
<tr>
<td>52</td>
<td>Sale of new drug for emergency treatment</td>
<td>Information and material to support the sale of a new drug to be used in the emergency treatment of a food-producing animal</td>
<td>102</td>
<td>102</td>
<td>102</td>
<td>102</td>
<td>102</td>
<td>102</td>
<td>102</td>
</tr>
<tr>
<td>53</td>
<td>Experimental studies certificate</td>
<td>Information and material to support the issuance of an experimental studies certificate for a drug to be administered to a non-food-producing animal</td>
<td>980</td>
<td>980</td>
<td>980</td>
<td>980</td>
<td>980</td>
<td>980</td>
<td>980</td>
</tr>
<tr>
<td>54</td>
<td>Experimental studies certificate</td>
<td>Information and material to support the issuance of an experimental studies certificate whose protocol is the same as that of a previously authorized experimental studies certificate for a drug to be administered to a non-food-producing animal</td>
<td>490</td>
<td>490</td>
<td>490</td>
<td>490</td>
<td>490</td>
<td>490</td>
<td>490</td>
</tr>
<tr>
<td>55</td>
<td>Experimental studies certificate</td>
<td>Information and material to support the issuance of an experimental studies certificate for a drug to be administered to a food-producing animal</td>
<td>2,958</td>
<td>2,958</td>
<td>2,958</td>
<td>2,958</td>
<td>2,958</td>
<td>2,958</td>
<td>2,958</td>
</tr>
<tr>
<td>56</td>
<td>Experimental studies certificate</td>
<td>Information and material to support the issuance of an experimental studies certificate whose protocol is the same as that of a previously authorized experimental studies certificate for a drug to be administered to a food-producing animal</td>
<td>490</td>
<td>490</td>
<td>490</td>
<td>490</td>
<td>490</td>
<td>490</td>
<td>490</td>
</tr>
<tr>
<td>57</td>
<td>Notifiable change</td>
<td>Information and material to support an application for a notifiable change</td>
<td>1,658</td>
<td>2,073</td>
<td>2,591</td>
<td>3,095</td>
<td>3,537</td>
<td>3,978</td>
<td>4,420</td>
</tr>
<tr>
<td>58</td>
<td>Protocol</td>
<td>A protocol that is filed with the Minister and may support a new drug submission, an abbreviated new drug submission, a supplement to a new drug submission or abbreviated new drug submission, a preclinical submission or information and material that is filed for the purpose of obtaining an experimental studies certificate</td>
<td>1,658</td>
<td>2,073</td>
<td>2,591</td>
<td>3,095</td>
<td>3,537</td>
<td>3,978</td>
<td>4,420</td>
</tr>
</table>


<a name='fn_1'><sup>1</sup></a>: This item applies only to an application for a drug identification number that does not include either of the components set out in items 1 and 2.<br />

<a name='fn_2'><sup>2</sup></a>: This item applies only to a new drug submission that does not include any of the components set out in items 5 to 17.<br />

<a name='fn_3'><sup>3</sup></a>: This item applies only to a supplement to a new drug submission that does not include any of the components set out in items 19 to 36.<br />

<a name='fn_4'><sup>4</sup></a>: This item applies only to an abbreviated new drug submission or a supplement to an abbreviated new drug submission that does not include any of the components set out in items 38 to 41.<br />



### **SCHEDULE 3** 
**(Sections 33 to 39 and 41 to 47)**
<table>
<h4>Fees for Examination of an Application for an Establishment Licence — Drugs for Human Use</h4>
<tr>
<th>Item</th>
<th>Column 1</th>
<th>Column 2</th>
<th>Column 3</th>
<th>Column 4</th>
<th>Column 5</th>
</tr>
<tr>
<th>Activity</th>
<th>Fee ($)</th>
<th>Fee ($)</th>
<th>Fee ($)</th>
<th>Fee ($)</th>
</tr>
<tr>
<th>Fiscal Year</th>
<th>Fiscal Year</th>
<th>Fiscal Year</th>
<th>Fiscal Year</th>
</tr>
<tr>
<th>2020-2021</th>
<th>2021-2022</th>
<th>2022-2023</th>
<th>2023-2024</th>
</tr>
<tr>
<td>1</td>
<td>Fabrication — sterile dosage form</td>
<td>41,626</td>
<td>41,730</td>
<td>41,834</td>
<td>41,937</td>
</tr>
<tr>
<td>2</td>
<td>Importation</td>
<td>27,359</td>
<td>29,033</td>
<td>30,707</td>
<td>32,380</td>
</tr>
<tr>
<td>3</td>
<td>Fabrication — non-sterile dosage form</td>
<td>27,000</td>
<td>28,364</td>
<td>29,727</td>
<td>31,091</td>
</tr>
<tr>
<td>4</td>
<td>Distribution</td>
<td>12,560</td>
<td>13,882</td>
<td>15,205</td>
<td>16,527</td>
</tr>
<tr>
<td>5</td>
<td>Wholesaling</td>
<td>4,937</td>
<td>6,171</td>
<td>7,715</td>
<td>9,644</td>
</tr>
<tr>
<td>6</td>
<td>Packaging/labelling</td>
<td>6,061</td>
<td>6,061</td>
<td>6,061</td>
<td>6,061</td>
</tr>
<tr>
<td>7</td>
<td>Testing</td>
<td>2,560</td>
<td>3,200</td>
<td>4,001</td>
<td>5,002</td>
</tr>
</table>




### **SCHEDULE 4** 
**(Sections 33 to 39 and 41 to 47)**
<table>
<h4>Fees for Examination of an Application for an Establishment Licence — Drugs for Veterinary Use Only</h4>
<tr>
<th>Item</th>
<th>Column 1</th>
<th>Column 2</th>
<th>Column 3</th>
<th>Column 4</th>
<th>Column 5</th>
<th>Column 6</th>
<th>Column 7</th>
<th>Column 8</th>
</tr>
<tr>
<th>Activity</th>
<th>Fee ($)</th>
<th>Fee ($)</th>
<th>Fee ($)</th>
<th>Fee ($)</th>
<th>Fee ($)</th>
<th>Fee ($)</th>
<th>Fee ($)</th>
</tr>
<tr>
<th>Fiscal Year</th>
<th>Fiscal Year</th>
<th>Fiscal Year</th>
<th>Fiscal Year</th>
<th>Fiscal Year</th>
<th>Fiscal Year</th>
<th>Fiscal Year</th>
</tr>
<tr>
<th>2020-2021</th>
<th>2021-2022</th>
<th>2022-2023</th>
<th>2023-2024</th>
<th>2024-2025</th>
<th>2025-2026</th>
<th>2026-2027</th>
</tr>
<tr>
<td>1</td>
<td>Fabrication — sterile dosage form</td>
<td>40,198</td>
<td>40,487</td>
<td>40,777</td>
<td>41,068</td>
<td>41,357</td>
<td>41,647</td>
<td>41,937</td>
</tr>
<tr>
<td>2</td>
<td>Importation</td>
<td>10,715</td>
<td>13,393</td>
<td>16,742</td>
<td>20,927</td>
<td>26,158</td>
<td>32,380</td>
<td>32,380</td>
</tr>
<tr>
<td>3</td>
<td>Fabrication — non-sterile dosage form</td>
<td>8,782</td>
<td>10,978</td>
<td>13,722</td>
<td>17,152</td>
<td>21,440</td>
<td>26,800</td>
<td>31,091</td>
</tr>
<tr>
<td>4</td>
<td>Distribution</td>
<td>4,835</td>
<td>6,043</td>
<td>7,555</td>
<td>9,443</td>
<td>11,803</td>
<td>14,754</td>
<td>16,527</td>
</tr>
<tr>
<td>5</td>
<td>Wholesaling</td>
<td>1,933</td>
<td>2,416</td>
<td>3,020</td>
<td>3,774</td>
<td>4,718</td>
<td>5,898</td>
<td>7,372</td>
</tr>
<tr>
<td>6</td>
<td>Packaging/labelling</td>
<td>6,061</td>
<td>6,061</td>
<td>6,061</td>
<td>6,061</td>
<td>6,061</td>
<td>6,061</td>
<td>6,061</td>
</tr>
<tr>
<td>7</td>
<td>Testing</td>
<td>1,315</td>
<td>1,644</td>
<td>2,055</td>
<td>2,569</td>
<td>3,210</td>
<td>4,013</td>
<td>5,002</td>
</tr>
</table>




### **SCHEDULE 5** 
**(Section 48)**
<table>
<h4>Fee Reduction — Application for an Establishment Licence — Drugs</h4>
<tr>
<th>Item</th>
<th>Column 1</th>
<th>Column 2</th>
</tr>
<tr>
<th>Percentage of Fee Reduction</th>
<th>Filing Period</th>
</tr>
<tr>
<td>1</td>
<td>25%</td>
<td>July 1 to September 30</td>
</tr>
<tr>
<td>2</td>
<td>50%</td>
<td>October 1 to December 31</td>
</tr>
<tr>
<td>3</td>
<td>75%</td>
<td>January 1 to March 31</td>
</tr>
</table>

**Note:** The fee payable under subsection 30(1) of this Order is not reduced if an application is filed on or after April 1 and up to and including June 30.





### **SCHEDULE 6** 
**(Section 52)**
## Fees for Right to Sell Drugs for Human Use

## Interpretation


**Definition of disinfectant**

**1** In this Schedule, ***disinfectant*** has the meaning assigned by the definition antimicrobial agent in subsection C.01A.001(1) of the [Food and Drug Regulations](/en/Regulations/Consolidated%20Regulations%20of%20Canada/801-900/C.R.C.,%20c.%20870.md).
<table>
<tr>
<th>Item</th>
<th>Column 1</th>
<th>Column 2</th>
<th>Column 3</th>
<th>Column 4</th>
<th>Column 5</th>
</tr>
<tr>
<th>Type of Drug</th>
<th>Fee ($)</th>
<th>Fee ($)</th>
<th>Fee ($)</th>
<th>Fee ($)</th>
</tr>
<tr>
<th>Fiscal Year</th>
<th>Fiscal Year</th>
<th>Fiscal Year</th>
<th>Fiscal Year</th>
</tr>
<tr>
<th>2020-2021</th>
<th>2021-2022</th>
<th>2022-2023</th>
<th>2023-2024</th>
</tr>
<tr>
<td>1</td>
<td>Disinfectant</td>
<td>1,285</td>
<td>1,344</td>
<td>1,403</td>
<td>1,462</td>
</tr>
<tr>
<td>2</td>
<td>Non-prescription drug</td>
<td>1,623</td>
<td>2,022</td>
<td>2,421</td>
<td>2,820</td>
</tr>
<tr>
<td>3</td>
<td>Drug other than one referred to in item 1 or 2</td>
<td>1,836</td>
<td>2,754</td>
<td>4,080</td>
<td>4,679</td>
</tr>
</table>






### **SCHEDULE 7** 
**(Section 56)**
<table>
<h4>Fees for Right to Sell Drugs for Veterinary Use Only</h4>
<tr>
<th>Item</th>
<th>Column 1</th>
<th>Column 2</th>
<th>Column 3</th>
<th>Column 4</th>
</tr>
<tr>
<th>Fee ($)</th>
<th>Fee ($)</th>
<th>Fee ($)</th>
<th>Fee ($)</th>
</tr>
<tr>
<th>Fiscal Year</th>
<th>Fiscal Year</th>
<th>Fiscal Year</th>
<th>Fiscal Year</th>
</tr>
<tr>
<th>2020-2021</th>
<th>2021-2022</th>
<th>2022-2023</th>
<th>2023-2024</th>
</tr>
<tr>
<td>1</td>
<td>312</td>
<td>367</td>
<td>422</td>
<td>477</td>
</tr>
</table>




### **SCHEDULE 8** 
**(Section 60)**
## Fees for Examination of an Application for a Medical Device Licence

## Interpretation


**Definition of private label medical device**

**1** In this Schedule, ***private label medical device*** means a medical device that is identical in every respect to a medical device in respect of which a licence has been issued, except that the device is labelled with the name and address of another manufacturer and the name and identifier of the device that the other manufacturer is proposing to sell under its own name or under a trademark, design, trade-name or other name or mark owned or controlled by it.


<table>
<tr>
<th>Item</th>
<th>Column 1</th>
<th>Column 2</th>
<th>Column 3</th>
<th>Column 4</th>
<th>Column 5</th>
<th>Column 6</th>
</tr>
<tr>
<th>Category</th>
<th>Description</th>
<th>Fee ($)</th>
<th>Fee ($)</th>
<th>Fee ($)</th>
<th>Fee ($)</th>
</tr>
<tr>
<th>Fiscal Year</th>
<th>Fiscal Year</th>
<th>Fiscal Year</th>
<th>Fiscal Year</th>
</tr>
<tr>
<th>2020-2021</th>
<th>2021-2022</th>
<th>2022-2023</th>
<th>2023-2024</th>
</tr>
<tr>
<td>1</td>
<td>Applications for Class II licence</td>
<td>Applications for Class II medical device licence other than those referred to in item 10</td>
<td>450</td>
<td>478</td>
<td>505</td>
<td>533</td>
</tr>
<tr>
<td>2</td>
<td>Applications for Class II licence amendment</td>
<td>Applications for amendment of Class II medical device licence other than those referred to in item 10</td>
<td>272</td>
<td>272</td>
<td>272</td>
<td>272</td>
</tr>
<tr>
<td>3</td>
<td>Applications for Class III licence</td>
<td>Applications for Class III medical device licence other than those referred to in item 4 or 10</td>
<td>7,477</td>
<td>8,912</td>
<td>10,347</td>
<td>11,783</td>
</tr>
<tr>
<td>4</td>
<td>Applications for Class III licence (near patient)</td>
<td>Applications for Class III medical device licence for a near patient in vitro diagnostic device</td>
<td>12,851</td>
<td>16,064</td>
<td>20,081</td>
<td>25,102</td>
</tr>
<tr>
<td>5</td>
<td>Applications for Class III licence amendment — changes in manufacturing</td>
<td>Applications for amendment of Class III medical device licence — changes in manufacturing process, facility or equipment or manufacturing quality control procedures</td>
<td>1,903</td>
<td>2,379</td>
<td>2,974</td>
<td>3,717</td>
</tr>
<tr>
<td>6</td>
<td>Applications for Class III licence amendment — significant changes not related to manufacturing</td>
<td>Applications for amendment of Class III medical device licence — significant changes other than those referred to in item 5</td>
<td>6,608</td>
<td>7,558</td>
<td>8,508</td>
<td>9,458</td>
</tr>
<tr>
<td>7</td>
<td>Applications for Class IV licence</td>
<td>Applications for Class IV medical device licence other than those referred to in item 10</td>
<td>24,345</td>
<td>24,748</td>
<td>25,151</td>
<td>25,554</td>
</tr>
<tr>
<td>8</td>
<td>Applications for Class IV licence amendment — changes in manufacturing</td>
<td>Applications for amendment of Class IV medical device licence — changes referred to in paragraph 34(a) of the [Medical Devices Regulations](/en/Regulations/Statutory%20Orders%20and%20Regulations/98/282.md) that relate to manufacturing</td>
<td>1,903</td>
<td>2,379</td>
<td>2,974</td>
<td>3,717</td>
</tr>
<tr>
<td>9</td>
<td>Applications for Class IV licence amendment — significant changes not related to manufacturing</td>
<td>Applications for amendment of Class IV medical device licence — any other changes referred to in paragraph 34(a) or (b) of the [Medical Devices Regulations](/en/Regulations/Statutory%20Orders%20and%20Regulations/98/282.md)</td>
<td>8,057</td>
<td>9,983</td>
<td>11,752</td>
<td>13,521</td>
</tr>
<tr>
<td>10</td>
<td>Applications for Class II, III or Class IV licence or licence amendment — private label medical device</td>
<td>Applications for Class II, III or IV medical device licence or applications for amendment of such a licence — private label medical device</td>
<td>147</td>
<td>147</td>
<td>147</td>
<td>147</td>
</tr>
</table>


